DAFALGAN Safety Questions, DAFALGAN Answers
More Here>>Side Effects - FDA Reports 2006-2008
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y ZWelcome! Patientsville.com provides unique information about DAFALGAN. Our extensive database of DAFALGAN adverse events and DAFALGAN warnings is updated regularly. If you have questions, you can post them to one of our health experts or ask others in our broad patient community.
>> Announcements
Check out our Hospital and Home Care Quality Reports.
Ask Our Health Experts about DAFALGAN
DAFALGAN Safety Reports
Total DAFALGAN reports: 7.DAFALGAN FDA safety alerts: No.
Reported hospitalizations: 5.
Take DAFALGAN Side Effects Survey or Share Your DAFALGAN Story. Read More Here.
Physician from FRANCE reported DAFALGAN problem on June 04, 2007. Female patient, 71 years of age, was diagnosed with pain in extremity, cardiac disorder, hypertension, varicose ulceration and was treated with DAFALGAN. After drug was administered, patient experienced the following problems/side effects: haematoma. DAFALGAN dosage: unknown. During the same period patient was treated with PRAVADUAL, ACETYLSALICYLIC ACID SRT, PREVISCAN, TENORMIN, AUGMENTIN, NUREFLEX. Patient recovered.
DAFALGAN problem was reported by a Physician from FRANCE on June 28, 2006. Male patient, 45 years of age, weighting 154.3 lb, was treated with DAFALGAN. After drug was administered, patient experienced the following problems/side effects: agranulocytosis. DAFALGAN dosage: unknown. During the same period patient was treated with KENACORT, SULFASALAZINE. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from FRANCE reported DAFALGAN problem on July 28, 2006. Female patient, 68 years of age, was diagnosed with pyelonephritis and was treated with DAFALGAN. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, gamma-glutamyltransferase increased, hepatitis, hyperbilirubinaemia. DAFALGAN dosage: unknown. During the same period patient was treated with OFLOCET, BISOPROLOL FUMARATE, RIFADIN, AMLODIPINE BESYLATE, TAREG. Patient was hospitalized. Patient recovered.
DAFALGAN problem was reported by a Health Professional from FRANCE on Aug 03, 2006. Female patient, 55 years of age, weighting 273.4 lb, was diagnosed with musculoskeletal pain, hypertension, skin ulcer, dysthymic disorder and was treated with DAFALGAN. After drug was administered, patient experienced the following problems/side effects: blood potassium increased, depressed level of consciousness, gastric ulcer perforation, peritoneal perforation, peritonitis, pneumoperitoneum, renal failure, sepsis, skin ulcer. DAFALGAN dosage: unknown. During the same period patient was treated with ALTEIS, PARIET, BUFLOMEDIL, SEROPRAM, PLAVIX. Patient recovered.
Consumer or non-health professional from SWITZERLAND reported DAFALGAN problem on Sept 01, 2006. Female patient, 70 years of age, was diagnosed with pain, sleep disorder, cough, hypercalcaemia of malignancy, bronchopneumonia and was treated with DAFALGAN. After drug was administered, patient experienced the following problems/side effects: agitation, bronchopneumonia, cough, gastrooesophageal reflux disease, grand mal convulsion, hypocalcaemia, hypothyroidism, overdose. DAFALGAN dosage: 4000 MG/D. During the same period patient was treated with ACIDUM FOLICUM STREULI, DISTRANEURIN, RESYL, HAEMODIALYSIS, ZOMETA, DEXAMETHASONE, LASIX, MERONEM. Patient was hospitalized. Patient recovered.
DAFALGAN problem was reported by a Consumer or non-health professional from FRANCE on July 28, 2006. Female patient, 68 years of age, weighting 207.2 lb, was diagnosed with pyelonephritis and was treated with DAFALGAN. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, cholestasis, gamma-glutamyltransferase increased, hepatitis, hyperbilirubinaemia, jaundice. DAFALGAN dosage: unknown. During the same period patient was treated with OFLOCET, BISOPROLOL FUMARATE, RIFADIN, AMLOR, TAREG, ORACEFAL. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from SWITZERLAND reported DAFALGAN problem on Sept 01, 2006. Female patient, 70 years of age, was diagnosed with pain, sleep disorder, cough, hypercalcaemia of malignancy, bronchopneumonia and was treated with DAFALGAN. After drug was administered, patient experienced the following problems/side effects: agitation, bronchopneumonia, cough, gastrooesophageal reflux disease, grand mal convulsion, hypocalcaemia, hypothyroidism, overdose. DAFALGAN dosage: 4000 MG/D. During the same period patient was treated with ACIDUM FOLICUM STREULI, DISTRANEURIN, RESYL, HAEMODIALYSIS, ZOMETA, DEXAMETHASONE, LASIX, MERONEM. Patient was hospitalized. Patient recovered.